异氰酸基环丁烷 | 5811-25-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 异氰酸基环丁烷
• 英文名称: cyclobutyl isocyanate
• 英文别名: isocyanatocyclobutane
• CAS: 5811-25-6
• 化学式: C₅H₇NO
• mdl: MFCD09938339
• 分子量: 97.1167
• InChiKey: JDUJUPAGCBYIRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2929109000

反应信息

• 作为反应物：
  描述：

  、 异氰酸基环丁烷 在 三乙胺 作用下， 生成
  参考文献：
  名称：

  zaragozic acid A衍生物的C1和C6侧链的构效关系。

  摘要：

  系统地修改了一种有效的角鲨烯合酶抑制剂za​​ragozic A的C6酰基侧链，以改善其生物学活性。将C6侧链简化为辛酸酯具有有害作用。增加线性链长度可提高体外活性，直至十四烷酸酯为止。ω-苯氧基比ω-苯基更好的活性增强剂。制备了许多C6氨基甲酸酯，醚和碳酸酯，发现它们具有与C6酯相似的活性。在制备C6醚时，还分离出C4和C4,6双醚。它们的相对活性为：C6> C4> C4,6。这些C6长链衍生物是亚纳摩尔角鲨烯合酶抑制剂。然而，它们仅在抑制小鼠肝胆固醇合成中具有弱活性。C6短链衍生物在体外的活性低得多，但它们在小鼠中的口服活性均得到改善。正丁酰基类似物的C1烷基侧链（ED50为4.5 mg / kg）的修饰不能进一步提高po活性。这些C6长链衍生物中的许多也是体外有效的抗真菌剂。

  DOI：

  10.1021/jm00049a022
• 作为产物：
  描述：

  Cyclobutanecarbonyl azide 反应 22.0h， 生成 异氰酸基环丁烷
  参考文献：
  名称：

  Synthesis and Quantitative Structure−Activity Relationship of Fatty Acid Amide Hydrolase Inhibitors: Modulation at the N-Portion of Biphenyl-3-yl Alkylcarbamates

  摘要：

  Alkylcarbamic acid biphenyl-3-yl esters are a class of fatty acid amide hydrolase (FAAH) inhibitors that comprises cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597), a compound with analgesic, anxiolytic-like and antidepressant-like properties in rat and mouse models. Here, we extended the structure-activity relationships (SARs) for this class of compounds by replacing the cyclohexyl ring of the parent compound cyclohexylcarbamic acid biphenyl-3-yl ester (URB524) (FAAH IC50 = 63 nM) with a selected set of substituents of different size, shape, flexibility, and lipophilicity. Docking experiments and linear interaction energy (LIE) calculations indicated that the N-terminal group of O-arylcarbamates fits within the lipophilic region of the substrate-binding site, mimicking the arachidonoyl chain of anandamide. Significant potency improvements were observed for the beta-naphthylmethyl derivative 4q (IC50 = 5.3 nM) and its 3'-carbamoylbiphenyl-3-yl ester 4z (URB880, IC50 = 0.63 nM), indicating that shape complementarity and hydrogen bonds are crucial to obtain highly potent inhibitors.

  DOI：

  10.1021/jm701631z

文献信息

• [EN] SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K1 TRICYCLIQUES SPIRO FUSIONNÉS
  申请人：BAYER AG

  公开号：WO2021074279A1

  公开（公告）日：2021-04-22

  The present invention relates to Map4K1 inhibitors of formula (I) to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及式(I)的MAP4K1抑制剂，以及包含根据本发明的化合物的药物组合物和组合物，以及创新化合物的预防性和治疗性用途，分别用于制造用于治疗或预防疾病的药物组合物，特别是用于肿瘤性疾病，癌症或与异常MAP4K1信号相关的其他紊乱免疫反应或其他紊乱的疾病，作为单一药剂或与其他活性成分组合使用。本发明还涉及使用，分别用于制造用于治疗或预防良性增生、动脉粥样硬化疾病、败血症、自身免疫疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制的蛋白抑制剂的药物组合物的用途。
• [EN] PREPARATION AND USE OF BICYCLIC HIMBACINE DERIVATIVES AS PAR-RECEPTOR ANTAGONISTS<br/>[FR] PRÉPARATION ET UTILISATION DE DÉRIVÉS BICYCLIQUES D'HIMBACINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE PAR
  申请人：MERCK SHARP & DOHME

  公开号：WO2013134012A1

  公开（公告）日：2013-09-12

  The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: X is -O-, -N(R), -C(R8)(R9) or -C(O)-; and Y is -O-, -N(R), -C(R8)(R9) or -C(O)- and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ACS, secondary prevention of myocardial infarction or stroke, or PAD.

  本发明涉及公式的双环希巴辛衍生物或其药用可接受盐，其中：X为-O-，-N(R)，-C(R8)(R9)或-C(O)-；Y为-O-，-N(R)，-C(R8)(R9)或-C(O)-，其余变量如本文所述。本发明的化合物是PAR-1受体的有效抑制剂。这些创新化合物可用于治疗或预防疾病状态，如急性冠状综合征（ACS），心肌梗死或中风的二级预防，或PAD。
• [EN] COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATIONS THEREOF AND USES THEREOF II<br/>[FR] COMPOSES, COMPOSITIONS CONTENANT CES COMPOSES, PREPARATION ET UTILISATIONS DE CES DERNIERS
  申请人：ASTRAZENECA AB

  公开号：WO2006033633A1

  公开（公告）日：2006-03-30

  Compounds of Formulae I, or pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4 and G are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  公式I的化合物，或其药用盐：（I）其中R1、R2、R3、R4和G如规范中定义的那样，以及包括这些化合物的盐和药用组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理方面。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：HAPLOGEN GMBH

  公开号：WO2018050631A1

  公开（公告）日：2018-03-22

  The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

  本发明涉及一般式（I）的新化合物，其中X和R1至R4基团的含义如描述和索赔中所述，制备这些化合物的方法以及它们作为治疗、预防或改善病毒感染的用途，以及用于治疗、预防或改善与PLA2G16相关的疾病的用途。
• Catalytic atroposelective dynamic kinetic resolutions and kinetic resolutions towards 3-arylquinolines<i>via</i>S_NAr
  作者：Mariel M. Cardenas、Mirza A. Saputra、Deane A. Gordon、Andrea N. Sanchez、Nobuyuki Yamamoto、Jeffrey L. Gustafson

  DOI：10.1039/d1cc04335h

  日期：——

  substitution (SNAr) of thiophenols into 3-aryl-2-fluoroquinolines mediated by catalytic amounts of Cinchona alkaloid-derived ureas. These reactions displayed a spectrum of dynamic kinetic resolution (DKR) and kinetic resolution (KR) characters depending upon the stereochemical stability of the starting material. Low barrier substrates proceeded via DKR while higher barrier substrates proceeded via

  在此，我们报道了通过催化量的金鸡纳生物碱衍生的脲介导的苯硫酚亲核芳香取代（S N Ar）成3-芳基-2-氟喹啉，催化对药学相关的3-芳基喹啉的催化选择性合成。这些反应显示出一系列动态动力学拆分 (DKR) 和动力学拆分 (KR) 特征，具体取决于起始材料的立体化学稳定性。低阻隔基材通过DKR 进行，而高阻隔基材则通过KR 进行。另一方面，具有中等稳定性的底物显示出 DKR 和 KR 的特征。最后，我们还表明，我们可以将富含阻转异构体的喹啉功能化为具有药学优势的支架，并且观察到的外消旋作用最少。